Drug intelligence / Profile preview

RGI-AB01

Development stage: Preclinical
Lead developer: REGiMMUNE
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

RGI-AB01 is a monoclonal antibody being developed by REGiMMUNE Corporation for the treatment of solid tumors. The drug is designed to suppress regulatory T cell (Treg) function by inhibiting the activity of a key mediator for immune suppression specifically expressed on Tregs in the tumor microenvironment. Unlike depletion-based strategies, RGI-AB01 utilizes a "silencing" approach, binding with high affinity to its target to modulate Treg activity and enhance anti-tumor immunity. The program is currently in the IND-enabling stage of development.

Targets

CCR8

Beyond the preview

Go deeper on RGI-AB01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RGI-AB01.

Explore the full profile